Nuformix

NFX · Main Market · Health Care · mcap £3.6m · 0.1p

Beta Briefing, track record and bull & bear case are not ready for Nuformix yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 58 companies are already wired into a briefing: browse them.

Key announcements Monitoring checked today, 19:05

All · 14 Key · 10

Date	Type	Announcement	Day
25 Aug 26	Board change	Appointment of Chairman Nuformix plc (LSE), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Tim Metcalfe as Non-Executive Chairman and a	−3.6%
19 Aug 26		NXP002 Development Update Nuformix plc (LSE), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to provide an update on progress with NXP002, the Company's lead programme	+32.1%
28 May 26	Results	Half-year Results Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces its unaudited results for the six months ended 31 March 2026.	−2.9%
11 Mar 26	Fundraise	£1.0 million Placing Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces a placing (the "Placing") to raise gross proceeds of £1.0 million throug	−25.0%
10 Mar 26		Confirmation of US ODD for NXP002 in IPF Confirmation of US Orphan Drug Designation for NXP002 Programme in IPF	+15.4%
27 Jan 26	Results	Final Results Annual Results for the period ended 30 September 2025	−15.8%
12 Nov 25		Update re. US FDA ODD Application US FDA Orphan Drug Designation Application for NXP002 Programme in IPF	−15.2%
12 Nov 25	Results	Results of Underwritten Open Offer Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the results of its underwritten Open Offer to Qualifying Shareholders w	−15.2%
28 Oct 25	Fundraise	Underwritten Open Offer Underwritten Open Offer at 0.2p per Open Offer Share to raise £228,081	−1.5%
10 Oct 25		Change of Auditor Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the appointment of Kreston Reeves Audit LLP ("Kreston Reeves Audit") as	−5.4%

Company filings. Not investment advice.